More Study Needed of Possible Carcinogenesis of Winter Gas Additive

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

WASHINGTON--Although the chemical MTBE, added to gasoline in the winter to reduce the emission of carbon monoxide, does not pose a substantial human health risk, more study needs to be undertaken to assess both short- and long-term health effects, a National Research Council (NRC) committee said in its review of a draft of a federal report.

WASHINGTON--Although the chemical MTBE, added to gasoline in thewinter to reduce the emission of carbon monoxide, does not posea substantial human health risk, more study needs to be undertakento assess both short- and long-term health effects, a NationalResearch Council (NRC) committee said in its review of a draftof a federal report.

The federal study assessed the effects of methyl-tertiary-butylether (MTBE) on air and water quality, motor vehicles (fuel economyand engine performance), and public health.

In areas that have not met air quality standards for carbon monoxide,federal law requires the use of additives that increase oxygenlevels in gas during winter months when lower temperatures tendto cause vehicles to emit more carbon monoxide. However, availabledata indicate that oxygenated fuels reduce winter air levels ofcarbon monoxide by as little as 0% to about 10%, the committeesaid.

The NRC committee disagreed with the report's conclusion thatonly a small percentage of the population may be sensitive toMTBE, citing studies showing an increase in health problems amongworkers exposed to MTBE on the job.

In addition, the panel said, cancer estimates for MTBE were basedon animal models and should not be taken as conclusive. The committeerecommended that further investigations be made into MTBE as apotential carcinogen.

Recent Videos
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Related Content